Cerebrolysin reduces amyloid-beta aggregation, enhances clearance of existing plaques through microglial activation, and provides neuroprotection against amyloid toxicity through neurotrophic mechanisms. These effects show promise for Alzheimer's disease applications.
Alzheimer's research demonstrates Cerebrolysin reduces amyloid burden in animal models and improves cognition in patients with mild-to-moderate dementia.